SAKAR reports Rs 10.28 cr consolidated profit in Q1FY27
Operating profit was Rs 9.25 cr at a 12.68% margin, while other income and a 29.46% tax rate shaped reported earnings.
Filed 24 Jul 2026, 12:17 IST · SAKAR (SAKAR)
Key takeaways
- The consolidated quarter's 29.12% operating margin was the clearest operating read, while other income did not dominate reported profit.
- Management said Sakar executed more than 65 oncology product contracts and had over 50 commercial discussions underway in Q1FY27.
- The company said 261 global dossiers had been shared, including 178 submissions and 16 marketing authorisations received.
Q1FY27 consolidated operating read
Sakar's consolidated operating margin was 29.12% in Q1FY27. Other income of Rs 1.54 was a limited contributor relative to profit before tax of Rs 14.58, so reported earnings were primarily tied to operations rather than non-operating income. The 29.46% tax rate remains an important part of the bridge from pre-tax profit to net profit.
Oncology contracts add commercial momentum
Management said the company executed more than 65 oncology product contracts and had over 50 commercial discussions underway during the quarter. It also said the Zydus Lifesciences partnership for GCC and emerging markets became Sakar's 40th global anti-cancer product agreement. The presentation said Sakar established an oncology facility at Bavla with integrated API and finished-dosage-form capabilities.
Regulatory pipeline supports the business transition
The company said it is moving towards a more integrated, regulatory-driven model, supported by greater value-chain integration and stronger operational capabilities. Management said Sakar has 33 oncology technology-transfer projects underway with multiple pharmaceutical partners and has developed 21 APIs in-house. The company also said its regulatory pipeline supports market-share expansion and sustained earnings momentum.
What management said about FY27
Management said the expanding oncology portfolio, market access and export opportunities position Sakar for stronger momentum in FY27. It also said the growing regulatory approval pipeline supports the company's next phase of growth. These are management's stated expectations, rather than reported outcomes for the quarter.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹73 cr |
| Other income | ₹2 cr |
| Expenses | ₹52 cr |
| Operating profit | ₹21 cr |
| Operating margin (%) | 29.12% |
| Interest | ₹2 cr |
| Depreciation | ₹7 cr |
| Profit before tax | ₹15 cr |
| Tax | ₹4 cr |
| Net profit | ₹10 cr |
| EPS (₹) | ₹4.62 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Sakar executed more than 65 oncology product contracts and had over 50 commercial discussions underway in Q1FY27.
- Sakar shared 261 global dossiers, including 178 submissions and 16 marketing authorisations received.
Guidance & outlook
- The company expects stronger momentum in FY27 as its oncology business expands its portfolio, market access and export opportunities.
- The company says its growing regulatory approval pipeline supports its next phase of growth.
- The company expects the regulatory pipeline to support market-share expansion and sustained earnings momentum.
Expansion
- Sakar established an oncology facility at Bavla with integrated API and finished-dosage-form capabilities.
New orders
- The Zydus Lifesciences partnership for GCC and emerging markets became Sakar’s 40th global anti-cancer product agreement.
- Sakar executed more than 65 oncology product contracts during Q1FY27.
New initiatives
- Sakar is transitioning to an integrated, regulatory-driven business model with greater value-chain integration and stronger operational capabilities.
- The company has 33 oncology technology-transfer projects underway with multiple pharmaceutical partners.
- Sakar has developed 21 APIs in-house, including APIs with Written Confirmation and CEP applications in process.
What to watch
- Whether operating margin moves from the 29.12% reported in Q1FY27.
- Whether the more than 65 oncology product contracts begin contributing to reported revenue.
- Progress on the 261 global dossiers, including 178 submissions and 16 marketing authorisations.